Search

everythinglearnresearchcommunity

for

Search:↓

Some drugs can cause hair loss, change hair color and shape, or increase hair growth, and treatment may involve stopping the drug or using specific hair growth treatments.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Dermal Papilla cells are a promising tool for evaluating hair growth treatments.

Women with PCOS often have skin problems like excessive hair, acne, hair loss, and dark patches, which can be treated with hormonal and non-hormonal therapies.

The conclusion is that published guidelines are improving transgender medical care, but more research and education in transgender medicine are needed.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

Oxidative stress is a key factor in the development of Polycystic Ovary Syndrome, and weight management can improve symptoms.

SHBG may be a useful early indicator and treatment target for PCOS.

Menopause and aging can affect women's quality of life and sexuality, but hormone therapies may help alleviate these issues.

AMH helps estimate ovarian reserve but doesn't predict pregnancy chances; age is more important.

Prolactin may play a significant role in skin and hair health and could be a target for treating skin and hair disorders.

Eating healthy, exercising, and taking certain supplements can help manage Polycystic Ovary Syndrome symptoms.

The document concludes with guidance for doctors on diagnosing and treating hirsutism effectively and safely.

Hidradenitis suppurativa may be related to hormones and patients often have metabolic disorders; more research is needed to understand this connection.

The conclusion is that hirsutism should be diagnosed and treated because it affects quality of life and may signal other health problems.

PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.

Finasteride effectively reduces hair growth in women with polycystic ovary syndrome or idiopathic hirsutism.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Hirsutism is excessive male-pattern hair growth in women, often caused by hormonal imbalances, and requires ongoing treatment to manage.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

A team approach is crucial for managing PCOS, with dermatologists playing a key role.

The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

The document concludes that proper diagnosis and combined treatments are key for hirsutism management, and weight loss may help overweight patients.

Some growth factors, while important for normal body functions, can cause diseases when not regulated properly.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.